{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T07:15:17Z","timestamp":1789802117990,"version":"4.0.1"},"reference-count":36,"publisher":"BMJ","funder":[{"name":"The Australian National Health and Medical Research Council (NHMRC) under the Centre of Research Excellence scheme","award":["APP1198362"],"award-info":[{"award-number":["APP1198362"]}]},{"name":"NHMRC Practitioner Fellowship scheme","award":["APP1155810"],"award-info":[{"award-number":["APP1155810"]}]},{"name":"The University of Newcastle infrastructure programme","award":["No grant number"],"award-info":[{"award-number":["No grant number"]}]},{"name":"Department of Respiratory and Sleep Medicine Special Purpose account","award":["604637"],"award-info":[{"award-number":["604637"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2026,5,28]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal duration of maintenance macrolide antibiotic therapy in obstructive airway disease (OAD) remains unclear. This study evaluated the impact of de-escalating maintenance macrolide therapy during the Australian summer on OAD exacerbations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This double-blind, placebo-controlled, non-inferiority trial recruited 82 participants (mean age: 67.33\u00b113.13; 55% female) undergoing maintenance macrolide therapy for the management of asthma, chronic obstructive pulmonary disease or bronchiectasis. They were randomised to continue (continuation arm) or de-escalate macrolide therapy (de-escalation arm) at the start of the summer (December\u2013February). Follow-up interviews were conducted at 3, 6 and 9\u2009months. The primary outcome was acute exacerbations during the summer. Secondary outcomes included symptom control scores and time to first exacerbation. The non-inferiority margin was 20%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The acute exacerbation rates were 33.3% (14\/42) for the continuation arm and 50% (19\/38) for the de-escalation arm during the summer season. The primary analysis did not demonstrate non-inferiority (risk difference 16.2%; 95% CI \u22124.9% to 37.2%, with the upper bound exceeding the 20% non-inferiority margin). Symptom control was maintained and did not differ between arms. The time to first exacerbation was longer in the continuation arm (median 206 vs 90 days; HR 1.98, 95% CI 1.15 to 3.42; p=0.012).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Macrolide de-escalation was not found to be non-inferior to continued treatment in individuals with OAD. While some patients may be able to discontinue long-term macrolide therapy during the summer, there remains a risk of exacerbation recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ACTRN12620001263987.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2025-224164","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:20:32Z","timestamp":1785259232000},"page":"thorax-2025-224164","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of maintenance macrolide de-escalation during the Australian summer on exacerbations of obstructive airway diseases: a randomised, double-blind, placebo-controlled trial"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4182-6821","authenticated-orcid":false,"given":"Dennis","family":"Thomas","sequence":"first","affiliation":[{"name":"Centre of Excellence in Treatable Traits, Hunter Medical Research Institute Asthma and Breathing Programme, Newcastle, New South Wales, Australia"},{"name":"College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9890-3408","authenticated-orcid":false,"given":"Vanessa","family":"McDonald","sequence":"additional","affiliation":[{"name":"Centre of Excellence in Treatable Traits, Hunter Medical Research Institute Asthma and Breathing Programme, Newcastle, New South Wales, Australia"},{"name":"College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, New South Wales, Australia"},{"name":"Hunter New England Local Health District, John Hunter Hospital, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5676-6126","authenticated-orcid":false,"given":"Peter AB","family":"Wark","sequence":"additional","affiliation":[{"name":"Centre of Excellence in Treatable Traits, Hunter Medical Research Institute Asthma and Breathing Programme, Newcastle, New South Wales, Australia"},{"name":"College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, New South Wales, Australia"},{"name":"School of Translational Medicine, Monash University, Melbourne, Victoria, Australia"},{"name":"Cystic Fibrosis Service, The Alfred Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyamala","family":"Pradeepan","sequence":"additional","affiliation":[{"name":"College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, New South Wales, Australia"},{"name":"Hunter New England Local Health District, John Hunter Hospital, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Twaddell","sequence":"additional","affiliation":[{"name":"College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, New South Wales, Australia"},{"name":"Hunter New England Local Health District, John Hunter Hospital, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gillman","sequence":"additional","affiliation":[{"name":"Allergy, Asthma and Clinical Immunology, Alfred Health, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hew","sequence":"additional","affiliation":[{"name":"Allergy, Asthma and Clinical Immunology, Alfred Health, Melbourne, Victoria, Australia"},{"name":"School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Denton","sequence":"additional","affiliation":[{"name":"Allergy, Asthma and Clinical Immunology, Alfred Health, Melbourne, Victoria, Australia"},{"name":"School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9881-9895","authenticated-orcid":false,"given":"Joy","family":"Lee","sequence":"additional","affiliation":[{"name":"Allergy, Asthma and Clinical Immunology, Alfred Health, Melbourne, Victoria, Australia"},{"name":"School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia"},{"name":"Austin Health, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Chien","sequence":"additional","affiliation":[{"name":"Department of Sleep and Respiratory Medicine, Westmead Hospital, Westmead, New South Wales, Australia"},{"name":"School of Medicine, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Hinwood","sequence":"additional","affiliation":[{"name":"College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin S","family":"Harvey","sequence":"additional","affiliation":[{"name":"Centre of Excellence in Treatable Traits, Hunter Medical Research Institute Asthma and Breathing Programme, Newcastle, New South Wales, Australia"},{"name":"College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, New South Wales, Australia"},{"name":"Hunter New England Local Health District, John Hunter Hospital, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gijo","family":"Thomas","sequence":"additional","affiliation":[{"name":"Centre of Excellence in Treatable Traits, Hunter Medical Research Institute Asthma and Breathing Programme, Newcastle, New South Wales, Australia"},{"name":"College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Smith","sequence":"additional","affiliation":[{"name":"Centre of Excellence in Treatable Traits, Hunter Medical Research Institute Asthma and Breathing Programme, Newcastle, New South Wales, Australia"},{"name":"College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Arnold","sequence":"additional","affiliation":[{"name":"Hunter New England Local Health District, John Hunter Hospital, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G","family":"Gibson","sequence":"additional","affiliation":[{"name":"Centre of Excellence in Treatable Traits, Hunter Medical Research Institute Asthma and Breathing Programme, Newcastle, New South Wales, Australia"},{"name":"College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, New South Wales, Australia"},{"name":"Hunter New England Local Health District, John Hunter Hospital, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"2026072810202205000_thorax-2025-224164v1.1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2213-2600(20)30105-3","article-title":"Prevalence and attributable health burden of chronic respiratory diseases, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"8","author":"Soriano","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026072810202205000_thorax-2025-224164v1.2","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m234","article-title":"Trends and risk factors of mortality and disability adjusted life years for chronic respiratory diseases from 1990 to 2017: systematic analysis for the Global Burden of Disease Study 2017","volume":"368","author":"Li","year":"2020","journal-title":"BMJ"},{"key":"2026072810202205000_thorax-2025-224164v1.3","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2026072810202205000_thorax-2025-224164v1.4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200401-033OC"},{"key":"2026072810202205000_thorax-2025-224164v1.5","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200701-001FM"},{"key":"2026072810202205000_thorax-2025-224164v1.6","doi-asserted-by":"publisher","DOI":"10.1177\/2040622314532862"},{"key":"2026072810202205000_thorax-2025-224164v1.7","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00165106"},{"key":"2026072810202205000_thorax-2025-224164v1.8","article-title":"Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)","volume":"2018","author":"Herath","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2026072810202205000_thorax-2025-224164v1.9","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-2600(19)30191-2","article-title":"Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis","volume":"7","author":"Chalmers","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026072810202205000_thorax-2025-224164v1.10","article-title":"Macrolide antibiotics for bronchiectasis","volume":"3","author":"Kelly","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026072810202205000_thorax-2025-224164v1.11","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S181246"},{"key":"2026072810202205000_thorax-2025-224164v1.12","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Gibson","year":"2017","journal-title":"The Lancet"},{"key":"2026072810202205000_thorax-2025-224164v1.13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201809-1739OC"},{"key":"2026072810202205000_thorax-2025-224164v1.14","unstructured":"Pocket guide to copd: diagnosis, management and prevention: a guide for health professionals 2020, global initiative for chronic obstructive lung diseases (gold)."},{"key":"2026072810202205000_thorax-2025-224164v1.15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2019-000489","article-title":"British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease","volume":"7","author":"Smith","year":"2020","journal-title":"BMJ Open Respir Res"},{"key":"2026072810202205000_thorax-2025-224164v1.16","unstructured":"Global Initiative for Asthma . Global strategy for asthma management and prevention. 2020."},{"key":"2026072810202205000_thorax-2025-224164v1.17","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur Respir J"},{"key":"2026072810202205000_thorax-2025-224164v1.18","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02265-2016","article-title":"Prevention of COPD exacerbations: a European Respiratory Society\/American Thoracic Society guideline","volume":"50","author":"Wedzicha","year":"2017","journal-title":"Eur Respir J"},{"key":"2026072810202205000_thorax-2025-224164v1.19","unstructured":"Australian Asthma Handbook. Melbourne: National Asthma Council Australia, 2015."},{"key":"2026072810202205000_thorax-2025-224164v1.20","unstructured":"The copd-x plan: australian and new zealand guidelines for the management of chronic obstructive pulmonary disease 2019. Lung Foundation Australia and the Thoracic Society of Australia and New Zealand; 2019."},{"key":"2026072810202205000_thorax-2025-224164v1.21","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-212463"},{"key":"2026072810202205000_thorax-2025-224164v1.22","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S2213-2600(13)70038-9","article-title":"Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases","volume":"1","author":"Serisier","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2026072810202205000_thorax-2025-224164v1.23","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/imj.15216","article-title":"Patterns of azithromycin use in obstructive airway diseases: a real\u2010world observational study","volume":"52","author":"Thomas","year":"2022","journal-title":"Intern Med J"},{"key":"2026072810202205000_thorax-2025-224164v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.01.044"},{"key":"2026072810202205000_thorax-2025-224164v1.25","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.jaci.2017.01.028","article-title":"Seasonal variability of severe asthma exacerbations and clinical benefit from lebrikizumab","volume":"139","author":"Staton","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2026072810202205000_thorax-2025-224164v1.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.12.1942"},{"key":"2026072810202205000_thorax-2025-224164v1.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2026072810202205000_thorax-2025-224164v1.28","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00102509"},{"key":"2026072810202205000_thorax-2025-224164v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.09.008"},{"key":"2026072810202205000_thorax-2025-224164v1.30","first-page":"78605","article-title":"Non-inferiority clinical trials to establish effectiveness; guidance for industry; availability","volume":"81","year":"2016","journal-title":"Fed Regist"},{"key":"2026072810202205000_thorax-2025-224164v1.31","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Wong","year":"2012","journal-title":"The Lancet"},{"key":"2026072810202205000_thorax-2025-224164v1.32","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-1208-6","article-title":"Treatment failure and hospital readmissions in severe COPD exacerbations treated with azithromycin versus placebo - a post-hoc analysis of the BACE randomized controlled trial","volume":"20","author":"Vermeersch","year":"2019","journal-title":"Respir Res"},{"key":"2026072810202205000_thorax-2025-224164v1.33","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: what is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur Respir J"},{"key":"2026072810202205000_thorax-2025-224164v1.34","doi-asserted-by":"crossref","first-page":"111509","DOI":"10.1016\/j.jclinepi.2024.111509","article-title":"Stakeholder-informed positivity thresholds for disease markers and risk scores: a methodological framework and an application in obstructive lung disease","volume":"175","author":"Sadatsafavi","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"2026072810202205000_thorax-2025-224164v1.35","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.arbres.2021.09.018","article-title":"The Hidden and Unchecked Judgement Calls When Using Exacerbation History for Managing COPD","volume":"58","author":"Sadatsafavi","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"2026072810202205000_thorax-2025-224164v1.36","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-024-03653-0"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2025-224164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:20:35Z","timestamp":1785259235000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2025-224164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":36,"alternative-id":["10.1136\/thorax-2025-224164"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2025-224164","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]}}}